Giant Biogene Holding Valuation
Is 2367 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2367 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2367 (HK$49.85) is trading below our estimate of fair value (HK$97.92)
Significantly Below Fair Value: 2367 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2367?
Key metric: As 2367 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 2367's PE Ratio? | |
|---|---|
| PE Ratio | 26.4x |
| Earnings | CN¥1.77b |
| Market Cap | CN¥46.72b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.1x |
| Enterprise Value/EBITDA | 20.1x |
| PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does 2367's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.1x | ||
1044 Hengan International Group | 8.1x | 1.8% | HK$26.1b |
2145 Shanghai Chicmax Cosmetic | 15x | 24.6% | HK$12.3b |
6896 Golden Throat Holdings Group | 8.4x | n/a | HK$2.4b |
3828 Ming Fai International Holdings | 4.9x | n/a | HK$587.4m |
2367 Giant Biogene Holding | 26.4x | 23.4% | HK$50.3b |
Price-To-Earnings vs Peers: 2367 is expensive based on its Price-To-Earnings Ratio (26.4x) compared to the peer average (9.1x).
Price to Earnings Ratio vs Industry
How does 2367's PE Ratio compare vs other companies in the Asian Personal Products Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 2367 is expensive based on its Price-To-Earnings Ratio (26.4x) compared to the Asian Personal Products industry average (25.1x).
Price to Earnings Ratio vs Fair Ratio
What is 2367's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 26.4x |
| Fair PE Ratio | 24x |
Price-To-Earnings vs Fair Ratio: 2367 is expensive based on its Price-To-Earnings Ratio (26.4x) compared to the estimated Fair Price-To-Earnings Ratio (24x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | HK$49.85 | HK$60.05 +20.5% | 12.0% | HK$80.00 | HK$48.00 | n/a | 15 |
| Nov ’25 | HK$53.60 | HK$59.82 +11.6% | 11.8% | HK$80.00 | HK$48.00 | n/a | 15 |
| Oct ’25 | HK$50.95 | HK$56.53 +10.9% | 7.1% | HK$64.29 | HK$48.00 | n/a | 14 |
| Sep ’25 | HK$41.25 | HK$56.95 +38.1% | 7.5% | HK$63.94 | HK$48.00 | n/a | 11 |
| Aug ’25 | HK$39.95 | HK$57.08 +42.9% | 6.2% | HK$62.71 | HK$50.90 | n/a | 10 |
| Jul ’25 | HK$45.85 | HK$56.58 +23.4% | 4.8% | HK$60.83 | HK$52.00 | n/a | 10 |
| Jun ’25 | HK$49.45 | HK$56.04 +13.3% | 5.2% | HK$60.83 | HK$52.00 | n/a | 9 |
| May ’25 | HK$47.95 | HK$53.88 +12.4% | 6.0% | HK$59.10 | HK$48.00 | n/a | 8 |
| Apr ’25 | HK$42.55 | HK$53.53 +25.8% | 6.0% | HK$59.10 | HK$48.00 | n/a | 9 |
| Mar ’25 | HK$35.70 | HK$47.59 +33.3% | 12.5% | HK$62.00 | HK$41.96 | n/a | 9 |
| Feb ’25 | HK$31.95 | HK$48.30 +51.2% | 12.3% | HK$62.00 | HK$43.00 | n/a | 8 |
| Jan ’25 | HK$35.60 | HK$48.42 +36.0% | 12.8% | HK$62.00 | HK$43.00 | n/a | 7 |
| Dec ’24 | HK$35.65 | HK$48.33 +35.6% | 13.0% | HK$62.00 | HK$43.00 | n/a | 7 |
| Nov ’24 | HK$33.65 | HK$49.39 +46.8% | 14.0% | HK$62.00 | HK$43.00 | HK$53.60 | 5 |
| Oct ’24 | HK$33.95 | HK$49.39 +45.5% | 14.0% | HK$62.00 | HK$43.00 | HK$50.95 | 5 |
| Sep ’24 | HK$37.60 | HK$49.09 +30.6% | 15.7% | HK$62.00 | HK$43.00 | HK$41.25 | 4 |
| Aug ’24 | HK$35.35 | HK$51.00 +44.3% | 15.8% | HK$62.00 | HK$43.00 | HK$39.95 | 3 |
| Jul ’24 | HK$34.80 | HK$51.00 +46.6% | 15.8% | HK$62.00 | HK$43.00 | HK$45.85 | 3 |
| Jun ’24 | HK$33.60 | HK$49.67 +47.8% | 12.6% | HK$58.00 | HK$43.00 | HK$49.45 | 3 |
| May ’24 | HK$35.25 | HK$57.33 +62.6% | 1.6% | HK$58.00 | HK$56.00 | HK$47.95 | 3 |
| Apr ’24 | HK$48.00 | HK$58.33 +21.5% | 4.9% | HK$62.00 | HK$55.00 | HK$42.55 | 3 |
| Mar ’24 | HK$46.90 | HK$50.33 +7.3% | 17.5% | HK$58.00 | HK$38.00 | HK$35.70 | 3 |
| Feb ’24 | HK$40.50 | HK$41.27 +1.9% | 11.0% | HK$49.00 | HK$38.00 | HK$31.95 | 4 |
| Jan ’24 | HK$33.60 | HK$39.77 +18.3% | 5.2% | HK$43.00 | HK$38.00 | HK$35.60 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Shanghai Chicmax Cosmetic
HK$12.3b
A multi-brand cosmetics company, engages in the research, development, manufacture, and sale of skincare, maternity, and childcare products in China.
2145
HK$30.95
7D
-7.6%
1Y
32.3%
Cheerwin Group
HK$2.6b
An investment holding company, manufactures and trades household insecticides and repellents, household cleaning, air care, personal care, pets and pet products, and other products in the People’s Republic of China.
6601
HK$1.93
7D
-2.5%
1Y
27.0%
Evergreen Products Group
HK$336.3m
An investment holding company, designs, manufactures, trades in, and sells hair products in the United States, the People’s Republic of China, the United Kingdom, Japan, Germany, and internationally.
1962
HK$0.52
7D
0%
1Y
-14.8%